BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28273485)

  • 21. Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials.
    Bando H; Rubinstein L; Harris P; Yoshino T; Doi T; Ohtsu A; Welch J; Takebe N
    Gastric Cancer; 2017 May; 20(3):481-488. PubMed ID: 27510411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
    Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O
    Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates.
    Gurung A; Hung T; Morin J; Gilks CB
    Histopathology; 2013 Jan; 62(1):59-70. PubMed ID: 23240670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
    Fennelly D; Aghajanian C; Shapiro F; O'Flaherty C; McKenzie M; O'Connor C; Tong W; Norton L; Spriggs D
    J Clin Oncol; 1997 Jan; 15(1):187-92. PubMed ID: 8996141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Management of hereditary ovarian cancer].
    Joó JG; Ládi S; Nagy BZ; Langmár Z
    Orv Hetil; 2011 Oct; 152(40):1596-608. PubMed ID: 21945869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.
    Garrido-Laguna I; Janku F; Vaklavas C; Falchook GS; Fu S; Hong DS; Naing A; Tsimberidou AM; Wen S; Kurzrock R
    Cancer; 2012 Mar; 118(5):1422-8. PubMed ID: 21823111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
    Emons G; Gorchev G; Sehouli J; Wimberger P; Stähle A; Hanker L; Hilpert F; Sindermann H; Gründker C; Harter P
    Gynecol Oncol; 2014 Jun; 133(3):427-32. PubMed ID: 24713545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.
    Posadas EM; Liel MS; Kwitkowski V; Minasian L; Godwin AK; Hussain MM; Espina V; Wood BJ; Steinberg SM; Kohn EC
    Cancer; 2007 Apr; 109(7):1323-30. PubMed ID: 17330838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.
    Chan JK; Tian C; Fleming GF; Monk BJ; Herzog TJ; Kapp DS; Bell J
    Gynecol Oncol; 2010 Mar; 116(3):301-6. PubMed ID: 19945740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial outcomes in older patients with advanced solid tumours.
    Khan KH; Yap TA; Ring A; Molife LR; Bodla S; Thomas K; Zivi A; Smith A; Judson I; Banerji U; de Bono JS; Kaye SB
    Br J Cancer; 2016 Feb; 114(3):262-8. PubMed ID: 26757260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary debulking surgery versus neo-adjuvant chemotherapy in stage III/IV ovarian cancer: Comparison of perioperative morbidity and survival data in Pakistani women.
    Chishti U; Aziz AB
    J Pak Med Assoc; 2015 Mar; 65(3):306-9. PubMed ID: 25933567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
    Glaser G; Weroha SJ; Becker MA; Hou X; Enderica-Gonzalez S; Harrington SC; Haluska P
    PLoS One; 2015; 10(5):e0126867. PubMed ID: 25962155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer.
    Rosen DG; Yang G; Cai KQ; Bast RC; Gershenson DM; Silva EG; Liu J
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):632-7. PubMed ID: 15701850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.
    Borgoño CA; Kishi T; Scorilas A; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP
    Clin Cancer Res; 2006 Mar; 12(5):1487-93. PubMed ID: 16533772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
    Matsuo K; Bond VK; Im DD; Rosenshein NB
    Am J Clin Oncol; 2010 Aug; 33(4):358-63. PubMed ID: 19875949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
    Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A
    Lancet; 2010 Jul; 376(9737):245-51. PubMed ID: 20609468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients.
    Samimi G; Varki NM; Wilczynski S; Safaei R; Alberts DS; Howell SB
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5853-9. PubMed ID: 14676106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of MDR1 in epithelial ovarian cancer and its association with disease progression.
    Lu L; Katsaros D; Wiley A; Rigault de la Longrais IA; Puopolo M; Yu H
    Oncol Res; 2007; 16(8):395-403. PubMed ID: 17913048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.